S148: TIME‐LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4‐YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL

Saved in:
Bibliographic Details
Published in:HemaSphere 2023-08, Vol.7 (S3), p.e10648ed-n/a
Main Authors: Kater, Arnon, Dubois, Julie, Brieghel, Christian, Kersting, Sabina, Enggaard, Lisbeth, Veldhuis, Gerrit, Mous, Rogier, Mellink, Clemens, Dobber, Johan, Poulsen, Christian, Da Cunha‐Bang, Caspar, Fredriksen, Hendrik, Janssens, Ann, Schjodt, Ida, Dompeling, Ellen, Ranti, Juha, Mattsson, Mattias, Bellido, Mar, Tran, Hoa, Nasserinejad, Kazem, Levin, Mark‐David, Niemann, Carsten
Format: Article
Language:English
Subjects:
Oral Sessions
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2572-9241
2572-9241
DOI:10.1097/01.HS9.0000967504.10648.ed